(Q37071192)

18 August 2017

1 reference

title

An update on huperzine A as a treatment for Alzheimer's disease (English)

1 reference

18 August 2017

0 references

3

Paul S Aisen

1 reference

18 August 2017

John T Little

1

1 reference

18 August 2017

Sally Walsh

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Investigational Drugs

18 August 2017

published in

1 reference

18 August 2017

volume

17

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

209-215

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

18 August 2017

1 reference

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Mechanism of inhibition of cholinesterases by huperzine A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Huperzine A from Huperzia species--an ethnopharmacolgical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Molecular forms of acetylcholinesterase in brain, nerve and muscle: Nature, localization and dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Preclinical evidence of neuroprotection by cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Huperzine A: A novel acetylcholinesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.209

10.1517/13543784.17.2.209

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference